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Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like
progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to
sites of tissue injury. Here, we evaluated the effect of the DPP4 inhibitor sitagliptin on eMSC in women with RPL,
determined the impact on endometrial decidualization, and assessed the feasibility of a full-scale clinical trial.
Methods: A double-blind, randomised, placebo-controlled feasibility trial on women aged 18 to 42 years with
a history of 3 or more miscarriages, regular menstrual cycles, and no contraindications to sitagliptin. Thirty-
eight subjects were randomised to either 100 mg sitagliptin daily for 3 consecutive cycles or identical placebo
capsules. Computer generated, permuted block randomisation was used to allocate treatment packs. Colony
forming unit (CFU) assays were used to quantify eMSC in midluteal endometrial biopsies. The primary out-
come measure was CFU counts. Secondary outcome measures were endometrial thickness, study acceptabil-
ity, and ﬁrst pregnancy outcome within 12 months following the study. Tissue samples were subjected to
explorative investigations.
Findings: CFU counts following sitagliptin were higher compared to placebo only when adjusted for baseline
CFU counts and age (RR: 1.52, 95% CI: 1.321.75, P<0.01). The change in CFU count was 1.68 in the sitagliptin
group and 1.08 in the placebo group. Trial recruitment, acceptability, and drug compliance were high. There
were no serious adverse events. Explorative investigations showed that sitagliptin inhibits the expression of
DIO2, a marker gene of senescent decidual cells.
Interpretation: Sitagliptin increases eMSCs and decreases decidual senescence. A large-scale clinical trial evaluat-
ing the impact of preconception sitagliptin treatment on pregnancy outcome in RPL is feasible and warranted.
Funding: Tommy’s Baby Charity.
Clinical trial registration: EU Clinical Trials Register no. 2016-001120-54.
Crown Copyright © 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Recurrent pregnancy loss (RPL), deﬁned as two or more spontane-
ous pregnancy losses prior to foetal viability, is a devastating disorder
for which there are few effective treatment options [1,2]. An esti-
mated 5% of women will experience two consecutive miscarriages
and 1% three or more losses [3]. The most common cause of sporadic(non-recurrent) pregnancy loss is foetal chromosome errors, some of
which are linked to maternal age [46]. Although consecutive preg-
nancies with foetal chromosomal aberrations can account for RPL [7],
the frequency of euploid miscarriage increases with each additional
loss [8,9]. These epidemiological observations suggest that uterine
factors are a major cause of higher-order miscarriages [8].
Based on an unbiased genome-wide DNA methylation analysis,
we reported recently that RPL is associated with loss of a conspicuous
epigenetic stem cell signature in endometrial stromal cells (EnSC)
isolated from midluteal biopsies [10]. Colony-forming unit (CFU)
assays conﬁrmed a reduction in endometrial mesenchymal stem-like
progenitor cells (eMSC) in RPL. Further, loss of eMSC has been linked
Research in context
Evidence before this study
Recurrent pregnancy loss (RPL) is a prevalent disorder for
which there are few effective treatment options. Loss of endo-
metrial plasticity, deﬁned by a reduction in endometrial mesen-
chymal stem-like progenitor cells (eMSC) and increased
abundance of senescent decidual cells, during the midluteal
window of implantation has been linked to RPL. Endometrial
homoeostasis and cyclic regeneration following menstrual
shedding are dependant, at least partly, on recruitment and
engraftment of bone marrow-derived cells (BMDC) and their
subsequent differentiation into non-hematopoietic endometrial
cell lineages, including decidual cells. Dipeptidyl-peptidase IV
(DPP4) inhibitors, such as sitagliptin, increase the bioavailabil-
ity of stromal cell-derived factor-1a, a potent chemoattractant
implicated in homing and engraftment of BMDC to sites of tis-
sue injury. Whether or not sitagliptin, an oral antidiabetic drug,
can be used to increase the abundance of eMSC during the
implantation window in RPL patients is not known.
Added value of this study
This double-blind, randomised, placebo-controlled trial demon-
strates that sitagliptin (100 mg daily) over 3 consecutive men-
strual cycles is effective in increasing the abundance of clonal
eMSC during the midluteal phase of the cycle. The increase in
eMSC in response to sitagliptin treatment was paralleled by a
decrease in the expression of DIO2, a marker gene of senescent
decidual cells. We found no evidence that sitagliptin at the con-
centration used inhibits endometrial DPP4 activity or impacts
directly on the clonogenicity of endometrial progenitor cells.
Pre-conceptual sitagliptin treatment was acceptable to RPL
patients and drug compliance was high. No serious adverse
events were reported.
Implications of all the available evidence
To our knowledge, this is the ﬁrst evidence that endometrial
plasticity during the implantation window can be enhanced
pharmacologically in RPL patients. The effectiveness of pre-
conception sitagliptin treatment in miscarriage prevention
warrants further testing in a large clinical trial.
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cess of intense tissue remodelling that transforms the cycling endo-
metrium upon embryo implantation into a semi-permanent tissue,
the decidua, capable of accommodating the rapidly expanding pla-
centa in pregnancy [12]. This multi-step process, driven by the posto-
vulatory rise in circulating progesterone and rising intracellular
cyclic adenosine monophosphate levels [13,14], starts with an acute
stress response that leads to differentiation of EnSC into specialised
decidual cells [11,15,16]. However, a sizeable population of EnSC fail
to differentiate and emerge as acute senescent decidual cells [11].
Cellular senescence is deﬁned by a state of permanent cell-cycle
arrest and secretion of inﬂammatory mediators, chemokines, growth
factors, and extracellular matrix (ECM) proteinases, referred to as the
senescence-associated secretory phenotype (SASP) [1719]. In
chronic senescence associated with ageing, the SASP is responsible
for disruption of normal tissue architecture and function through
diverse mechanisms, including excessive ECM remodelling, recruit-
ment of inﬂammatory immune cells, and inhibition of stem cell func-
tion [18,19]. By contrast, acute senescent cells are involved in tightly
orchestrated biological processes, such as wound healing, tissue
repair and embryo development, and produce a SASP with deﬁnedPlease cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://doparacrine functions [2022]. Also, acute senescent cells typically self-
organise their elimination by recruiting innate immune cells, fore-
most natural killer (NK) cells [18,23,24]. These deﬁning characteris-
tics also apply to the midluteal endometrium. For example, the initial
inﬂammatory decidual ‘secretome’ has been shown experimentally
to induce expression of key endometrial receptivity genes [25]. Fur-
ther, we demonstrated that decidual cells orchestrate the elimination
of their senescent counterparts by secreting factors, such as interleu-
kin 15 (IL-15) and C-X-C motif chemokine ligand 14 (CXCL14),
involved in recruitment and activation of uterine NK cells [11],
de facto curtailing tissue inﬂammation and facilitating transformation
of the stroma into the decidua of pregnancy. Based on marker genes
of decidual subsets identiﬁed by high-throughput single-cell RNA-
sequencing, we demonstrated that the midluteal endometrium in
RPL is associated not only with eMSC deﬁciency but also excessive
decidual senescence [26], an imbalance that arguably predisposes to
the formation of a proinﬂammatory and intrinsically unstable placen-
tal-decidual interface in pregnancy.
Decidual cells but not senescent decidual cells are dependant on
continuous progesterone signalling [26]. Consequently, in the
absence of embryo implantation, falling ovarian progesterone pro-
duction leads to a preponderance of senescent cells and activation of
a cascade of events that result in tissue breakdown, bleeding and
menstrual shedding of the superﬁcial endometrial layer [27,28]. It is
widely accepted that cyclic endometrial repair following menstrual
injury involves activation of epithelial progenitor cells and eMSC
residing in the basal layer [2931]. However, bone marrow trans-
plantation studies in humans and mice have provided compelling
evidence that endometrial regeneration and homoeostasis also
depend, at least partly, on recruitment and engraftment of bone mar-
row-derived cells (BMDC) and their subsequent differentiation into
non-hematopoietic endometrial lineages, including endothelial, stro-
mal and epithelial cells [3236]. Stromal cell-derived factor-1a (SDF-
1), also known as CXCL12, is a potent chemotactic factor that medi-
ates mobilization of BMDC and homing to the endometrium in
response to tissue injury and rising oestradiol levels [37,38]. How-
ever, SDF-1 is proteolytically inactivated by dipeptidyl-peptidase IV
(DPP4), a ubiquitous aminopeptidase expressed both as a cell sur-
face-bound protein and in soluble form [39]. DPP4 inhibitors (glip-
tins) are commonly used oral antidiabetic drugs for the treatment of
type 2 diabetes [40]. They improve glucose homoeostasis by prevent-
ing degradation of the incretin hormones glucagon-like peptide-1
and glucose-dependant insulinotropic polypeptide [41]. In addition,
numerous preclinical studies reported that DPP4 inhibitors confer
cardiovascular protection and promote tissue regeneration following
injury by increasing SDF-1 bioactivity, although the results of clinical
trials to date have been more ambiguous [39,40,42,43]. Gliptins have
a good safety proﬁle, do not cause hypoglycaemic episodes, and are
well-tolerated in both diabetic and nondiabetic patients [40].
Based on these observations, we hypothesised that sitagliptin,
given over multiple menstrual cycles, will enhance the abundance of
eMSC in RPL patients. To test this hypothesis, we carried out a rando-
mised, double-blind, placebo-controlled feasibility trial. Tissue sam-
ples obtained during the study and primary cultures were subjected
to additional analysis to explore the mechanisms of sitagliptin actions
in the endometrium and to assess the impact on decidual subpopula-
tions.
2. Materials and methods
2.1. Study governance
The SIMPLANT study was approved by the Medicines and Health-
care Regulatory Authority (MHRA), the National Health Service
Research Ethics Committee South Central-Hampshire B (16/SC/0229)
and Research, Development and Innovation (RD&I) ofﬁce attrial mesenchymal stem-like progenitor cells: A randomised, double-
i.org/10.1016/j.ebiom.2019.102597
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Health Service (NHS) Trust. The study was sponsored by UHCW NHS
Trust and funded by Tommy’s baby charity (registered charity
1,060,508/ SC039280, Great Britain). The study protocol was submitted
to the EU Clinical Trials Register (EudraCT number 2016-001120-54
issued 25th July 2016) and is available on-line (clinicaltrialsregister.eu).
The date of enrolment of ﬁrst participant was 15th September 2016.
2.2. Participants
This was a single-centre trial. Participants were recruited from a
tertiary recurrent miscarriage clinic at UHCWNHS Trust. Women were
eligible if aged between 18 and 42 years, had a history of 3 or more
consecutive miscarriages, and regular menstrual cycles (up to 30 days
in length). All participants were deemed to have unexplained miscar-
riages following standard RPL investigations. Participants agreed to
actively avoid pregnancy and use barrier contraception for the dura-
tion of the trial. Exclusion criteria were diabetes mellitus and contrain-
dications for the use of sitagliptin: history of pancreatitis, renal or
hepatic impairment, taking digoxin or enalapril, and breastfeeding.
2.3. Sample size
Sample size was determined by a power calculation based on pre-
viously reported data [10]. Using a Poisson model and simulations, a
sample size of 30 participants was calculated to have 91% power at
5% signiﬁcance level to detect a difference when the mean CFU counts
for placebo and sitagliptin groups are 3.4 and 6 per 1000 EnSC,
respectively. To allow for drop-out, the planned minimum sample
size was 34 women. Recruitment to the study was stopped after 30
women completed the study.
2.4. Intervention and control groups
The intervention group were allocated packs containing sitaglip-
tin (100 mg) that had been encapsulated by Sharp Clinical Services
(Powys, UK). Participants were instructed to take the capsules once
daily from the day of the baseline biopsy for 3 menstrual cycles until
the second biopsy was taken. The control group were allocated iden-
tical placebo capsules also supplied by Sharp Clinical Services and
instructed to take these exactly as the intervention group.
2.5. Randomisation and masking
The study statistician used the R statistical package to generate a
randomisation list of 40 participants using the permuted block ran-
domisation. The block sizes were 6, 8, 6, 8, 6 and 6. The ratio of women
in the two groups within a block was 1:1. An independent statistician
checked the R programme used to generate the randomisation list, the
ﬁnal randomisation lists, and the information inside all code break
envelopes. Only the statisticians were unblinded to the block sizes and
the master randomisation list. The statisticians were otherwise not
involved in trial execution. Participants, the trial team, and laboratory
staff were blinded to the medication assignment until completion of
the trial. Immediately following the baseline biopsy, the clinical team
contacted the RD&I ofﬁce at UHCW NHS Trust to request treatment
pack number allocation for each participant. These pack numbers
were then allocated to participants using the randomisation list. The
study statistician prepared a sealed code break envelope for each par-
ticipant, which was kept securely by the sponsor in case unblinding
was required. Unblinding was not needed in the trial.
2.6. Primary and secondary outcome measures
The primary outcome measure was the CFU count, assessed by
CFU assays, in midluteal biopsies. CFU count is a surrogate for eMSCPlease cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://docount. The primary outcome was measured at baseline (pre-treat-
ment) and following 3 cycles of placebo or sitagliptin (posttreat-
ment). The pre-planned primary analysis was to compare the
posttreatment CFU count per 1000 EnSC. The prespeciﬁed secondary
analysis was to compare the posttreatment CFU counts adjusted for
characteristics that were different between the placebo and sitaglip-
tin groups. Secondary outcome measures not included in the protocol
were endometrial thickness, study acceptability, and ﬁrst pregnancy
outcome within 12 months following the study. Tissue samples and
primary endometrial cell cultures were used to explore the mecha-
nisms of sitagliptin actions in the endometrium and to assess the
impact on decidualization. The methods used are described below.
2.7. Transvaginal ultrasound, endometrial biopsies and scheduled study
visits
Following written informed consent, participants were given a dig-
ital home ovulation test kit (Clearblue, Geneva, Switzerland), an emer-
gency contact card, and barrier contraception. Participants then
attended the clinic 710 days after the luteinizing hormone (LH) surge
(LH+710). A transvaginal pelvic ultrasound scan was performed after
a negative urinary pregnancy test. Endometrial thickness was deﬁned
as the maximal endometrium diameter measured in a midsagittal
plane. Next, an endometrial biopsy was obtained using a Wallach
Endocell endometrial sampler. The sample, designated ‘baseline
biopsy’, was immediately portioned with one part stored in RNALater
Stabilization Solution (Sigma-Aldrich, Dorset, UK), one part snap fro-
zen in liquid nitrogen, one part ﬁxed in 10% formalin for immunohis-
tochemistry, and the remainder placed in 10% DMEM/F12 for isolation
of primary EnSC (see below). Following randomisation, trial medica-
tion was provided and all participants attended two follow-up clinics
at 4 weeks § 4 days intervals. At these follow-up visits, a urine preg-
nancy test was carried out, symptom diaries were reviewed, adverse
events reported, and willingness for continued participation con-
ﬁrmed. At the second follow-up visit, participants were provided with
a home ovulation test kit. In the third cycle, participants attended the
clinic on LH+710 for a repeat transvaginal ultrasound scan with mea-
surement of endometrial thickness and endometrial biopsy. A second
endometrial sample, designated ‘second biopsy’, was obtained and
processed identically to the baseline biopsy. Trial medication was
stopped on the day of the second biopsy.
2.8. Study acceptability, compliance, adverse events and pregnancy
outcome
Participants were provided with compliance and symptom diaries
at each visit. Diaries were assessed at every follow-up or biopsy visit.
Acceptability and satisfaction of the study was assessed with a Likert
scale-based questionnaire completed by participants after their ﬁnal
visit. Participants who conceived after completion of the study were
requested to contact the trial team and outcome of the ﬁrst preg-
nancy within one year of study completion was recorded.
2.9. Isolation of primary EnSC
Primary EnSC were isolated according to our published protocol
[44]. Brieﬂy, samples were washed in DMEM/F-12 medium (Invitro-
gen), ﬁnely minced and enzymatically digested with 0¢5 mg/ml colla-
genase (Sigma-Aldrich) and 0¢1 mg/ml deoxyribonuclease type I
(Roche, Burgess Hill, UK) for 1 h in 5% CO2 at 37 °C. Stromal and epi-
thelial fractions were separated and cryopreserved in 10% DMSO in
dextran-coated charcoal-stripped foetal bovine serum (DCC; 2 ml per
vial; Invitrogen), with the stromal fraction split into two or three vials
depending on the biopsy size. After controlled cooling at80 °C over-
night, samples were transferred to liquid nitrogen for storage.trial mesenchymal stem-like progenitor cells: A randomised, double-
i.org/10.1016/j.ebiom.2019.102597
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All CFU assays were conducted in batches, consisting of paired pri-
mary EnSC isolated from baseline and second biopsies from 3 or 4 par-
ticipants. CFU assays were established as described previously [45].
Brieﬂy, cryopreserved EnSC were thawed for 3 min at 37 °C and then
transferred immediately into pre-warmed growth medium (DMEM-
F12 medium containing 10% DCC supplemented with 1% L-Glutamine
and 1% antibiotic-antimycotic mix; Invitrogen). Cells were pelleted by
centrifugation at 276£ g for 5 min, supernatant was aspirated and cells
were resuspended in 10 ml growthmedium. Viable EnSC were counted
in trypan blue on a Neubauer Improved haemocytometer and seeded
at clonal density (53 cells/cm2) onto ﬁbronectin-coated 6-well plates
[10 mg/ml in phosphate buffered saline (PBS); Sigma-Aldrich] in
growth medium supplemented with 10 ng/ml basic ﬁbroblast growth
factor (Sigma Aldrich). Three wells, containing 500 cells each, were
seeded per biopsy. Plates were cultured in 5% CO2 at 37 °C and left
undisturbed for 3 days after which growth was monitored to ensure
colonies arose from single cells. The culture media was half-changed
after 7 days of culture. On day 10, cultures were washed in PBS, ﬁxed in
10% neutral buffered formalin for 10 min at room temperature, washed
extensively in sterile water, and then stained with Harris hematoxylin
for 4 min. After extensive washing in sterile water, plates were incu-
bated in PBS for 4 min to intensify the stain. PBS was removed and
plates washed again in sterile water and then allowed to dry. Colonies
were imaged using a G:Box dark room imager and GeneSys software
(Syngene). Images were analysed in ImageJ by a single operator using
the cell counter plugin to count colonies of 50 cells or larger [10]. The
pre-speciﬁed primary outcome measure was the CFU count per 1000
EnSC seeded after 3 cycles of sitagliptin or placebo. However, to miti-
gate against potential loss of data in case of infection, a total of 1500
cells were seeded in 3 wells of a 6-well plate per sample. As there were
no obvious criteria to exclude the colony count from a given well, the
results are presented as CFU count per 1500 EnSC.2.11. DPP4 activity assay
DPP4 activity in whole tissue lysates from snap-frozen endome-
trial biopsies was measured using DPP4 Activity Assay Kit (Sigma-
Aldrich) according to the manufacturer's instructions. DPP4 activity
was normalised to total protein content. The Bradford assay was used
to measure protein concentrations (Sigma-Aldrich).2.12. Reverse transcription quantitative PCR (RT-qPCR)
RNAwas extracted from RNAlater-preserved tissue using the RNeasy
Lipid Tissue Mini Kit (QIAGEN, Manchester, UK) with on-column DNase
treatment and according to the manufacturer’s instructions. RNA was
assessed using a Nanodrop ND-1000 spectrophotometer and 1 mg RNA
used for reverse transcription using the Quantitect Reverse Transcrip-
tion Kit (QIAGEN) and according tomanufacturer’s instructions. Thermal
cycling was performed on a QuantStudio 5 Real-Time PCR System (Ther-
moFisher, Paisley, UK), using PrecisionPlus 2 £ Mastermix (Primer
Design, Southampton, UK), 300 nM forward and reverse primers, and
1 ml cDNA. L19 was used as a housekeeping gene and data were ana-
lysed using the Pfafﬂ method [46]. Primer sequences were as follows:
PRL (F) 50-AAG CTG TAG AGA TTG AGG AGC AAA C-30, PRL (R) 50-TCA
GGA TGA ACC TGG CTG ACT A-30; DPP4 (F) 50-CCA AAG ACT GTA CGG
GTTC C-30, DPP4 (R): 50-ACA AAG AAC TTT ACA GTT GGA TTC AC-30;
IGFBP1 (F) 50-CGA AGG CTC TCC ATG TCA CCA-30, IGFBP1 (R), 5-TGT CTC
CTG TGC CTT GGC TAA AC-3; SCARA5 (F) 50-CAT GCG TGG GTT CAA AGG
TG-30, SCARA5 (R) 50-CCA TTC ACC AGG CGG ATC AT-30; DIO2 (F) 50-ACT
CGG TCA TTC TGC TCA A-30, DIO2 (R) 50-TTC CAG ACG CAG CGC AGT-30;
L19 (F) 50-GCG GAA GGG TAC AGC CAA T-30, L19 (R) 50-GCA GCC GGC
GCA AA-30.Please cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://do2.13. In vitro sitagliptin experiments: DPP4 assay
Primary cultures of EnEC or EnSC were established as described
before [44]. Conﬂuent cultures were exposed to pharmacological
concentrations of sitagliptin for one hour [47]. Conditioned culture
media (culture supernatant) was collected and enzymatic activity of
secreted DPP4 measured using the DPP4 Activity Assay according to
the manufacturer’s instructions (Sigma-Aldrich).2.14. In vitro sitagliptin experiments: CFU and organoid forming
efﬁciency assays
CFU assays were performed on cultured EnSC at passage 2 in the
presence or absence of 100 mM sitagliptin. CFUs were ﬁxed, stained
and counted after 10 days in culture, as described in Section 2.10.
Epithelial gland organoids were established using a recently
described protocol [48]. To determine the impact of sitagliptin on epi-
thelial progenitors, EnEC were seeded at a density of 300 cells per
5 ml ice cold Matrigel (Corning) in 96-well plates. Matrigel was ﬁrst
polymerised at 37 °C for 45 min and then 100 ml organoid expansion
medium, containing epidermal growth factor, ﬁbroblast growth fac-
tor 10, hepatocyte growth factor, Noggin (BMP4 antagonist), R-spon-
din-1(WNT/b catenin pathway agonist), A83-01 (Alk3/4/5 inhibitor),
and nicotinamide, was added and supplemented with 100 mM sita-
gliptin or vehicle control. Medium was changed every 2 days and the
number of organoids per well was counted after 10 days. At least 3
wells per sample were counted and averaged. The following formula
was used to calculate organoid forming efﬁcacy: OFE (%) = (number
of organoids / cells seeded) £ 100.2.15. Statistical analysis
Trial data were analysed using R [49]. Participant characteristics
[age, body mass index (BMI), number of previous miscarriages] and
baseline and second CFU counts were summarised as the mean,
median, minimum, maximum, standard deviation and interquartile
range. Mann-Whitney U test was used to compare baseline charac-
teristics between the placebo and sitagliptin groups. The primary
analysis of the primary outcome ﬁtted a Poisson regression model to
compare the mean CFU count per 1500 EnSC following 3 cycles of
sitagliptin or placebo. As planned in the protocol, a secondary analy-
sis of the primary outcome adjusted for characteristics that were
imbalanced between control and intervention (i.e. age and baseline
CFU count) was performed. To estimate the increase from baseline, a
random effects Poisson regression model that consisted of the base-
line and second CFU counts was ﬁtted. The random effects model
included an interaction term for biopsy and group. An exploratory
subgroup analysis excluding 8 women with substantially higher
baseline CFU count (>20 colonies per 1500 cells seeded) was also
performed. For other secondary outcome measures, Kruskal-Wallis
with Dunn’s post-hoc test for multiple comparisons was used for
grouped analysis (endometrial thickness) and Mann-Whitney U test
was used for pairwise comparisons (LH timing). For exploratory anal-
yses, statistical tests were performed using GraphPad Prism (version
8.2.1). Wilcoxon matched-pairs signed rank test with Sidak correc-
tion for multiple testing (alpha = 0.025) was used to analyse differen-
ces in gene expression or DPP4 activity between the baseline and
second biopsy in either the sitagliptin or placebo group. Temporal
changes in relative gene expression or DPP4 activity between the pla-
cebo and sitagliptin groups was compared using Mann-Whitney
U test. DPP4 activity in EnEC and EnSC culture supernatants were
compared using Mann-Whitney U test. CFU activity and OFE in paired
cultures treated with or without sitagliptin were compared using
Wilcoxon matched-pairs signed rank test. Unless stated otherwise,
P < 0.05 was considered signiﬁcant.trial mesenchymal stem-like progenitor cells: A randomised, double-
i.org/10.1016/j.ebiom.2019.102597
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3.1. Patient recruitment and trial completion
The study was discussed with 73 patients with a severe RPL phe-
notype, deﬁned by the number of previous miscarriages and a history
of at least one euploid pregnancy loss conﬁrmed by cytogenetic anal-
ysis. Forty-two subjects consented to the study but four were lost
prior to randomisation: two withdrew consent, one participant had a
urea level outside the reference range, and insufﬁcient tissue was
obtained in the baseline biopsy of one participant. A total of 19
women were allocated to each treatment group. In the sitagliptin
group, 16 completed the study, one participant was withdrawn by
the sponsor, one opted-out and one was lost to follow-up. In the pla-
cebo group, two participants became pregnant during the trial and
17 completed the study. The CONSORT diagram is presented in Fig. 1.
The ﬁrst participant consented on 15 September 2016 and the last
participant to have a second biopsy attended on 16 February 2018.
Pregnancy follow-up was completed on 28 February 2019.
3.2. Patient characteristics and CFU counts
The median number of previous miscarriages in the sitagliptin
and placebo groups was 5¢5 and 8, respectively (Table 1), underscor-
ing the severity of the RPL phenotype of study participants. The num-
ber of previous pregnancy losses, BMI, day of the biopsy relative to
the LH-surge, and baseline CFU counts were not signiﬁcantlyCONSORT Flow
Assessed fo
Analysed  (n=15) 
♦ Excluded from analysis (n=1, biopsy not 
analysable due to contamination)
Lost to follow-up (n=1) 
Discontinued intervention (n=0)  
Allocated to Sitagliptin (n=19) 
♦ Received allocated intervention (n= 17)
♦ Did not receive allocated intervention (n= 2) 
Ineligible (n=1), consent withdrawn (n=1)
Alloca
Ana
Follow
Rando
Enrollment
Fig. 1. Consort ﬂo
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Table 1). However, the median age of participants in the sitagliptin
group was higher than in the placebo group (36 vs. 32 years, P = 0.02)
(Table 1).
The primary outcome measure was based on the CFU counts of the
second biopsies upon completion of the trial. Although 33 participants
completed the trial, second biopsy CFU counts were available for 32
subjects because of one case of yeast contamination in the sitagliptin
group. Conversely, the baseline count was lacking for one subject in
the placebo group as no viable cells were recovered. The primary out-
come analysis showed no signiﬁcant difference in the unadjusted
mean CFU count after 3 cycles of sitagliptin compared to placebo
(P = 0.15; Table 2). When adjusted for baseline CFU count, the mean
CFU count in the second biopsy was signiﬁcantly higher in the sitaglip-
tin group compared to the placebo group (27.67 vs. 25.06, RR: 1.51,
95% CI =1.311.73, P<0¢01). Adjusting for age and baseline CFU count
hadminimal impact on results (Table 2). Unadjusted subgroup analysis
that excluded 8 outlying CFU counts (>20 colonies per 1500 cells) also
demonstrated signiﬁcantly higher CFU counts following sitagliptin
treatment compared to placebo (14.42 vs. 11.00, RR: 1.31, 95% CI
=1.041.63, P = 0.02). As shown in Fig. 2, CFU count in the second
biopsy was signiﬁcantly higher when compared to the baseline biopsy
in the sitagliptin arm (median increase in colonies: +7 per 1500 cells,
1.68-fold the baseline count, P<0.01). By contrast, there was no signiﬁ-
cant increase in the CFU count between the baseline and second biopsy
in the placebo group (median increase:0.5 per 1500 cells, 1.08-fold
the baseline count, P = 0.26) (Fig. 2. and Table 3). Diagram 
r eligibility (n= 73) 
Excluded (n=35) 
♦ Not meeting inclusion criteria (n=7) 
♦ Declined to participate (n=24) 
♦ Other reasons (n= 4) 
Lost to follow-up (n=0) 
Discontinued intervention (n=2) (conceived 
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Allocated to placebo (n=19) 
♦ Received allocated intervention (n=19)
♦ Did not receive allocated intervention 
(n=0)
Analysed  (n=17) 
♦ Excluded from analysis (n=0)
tion
lysis
-Up
mized (n=38) 
w diagram.
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Table 1
Patient demographics and CFU counts at baseline and second biopsy.
Sitagliptin Group
(n = 16)
Placebo Group
(n = 17)
P-valuey
Age (years)
Median (IQR, Range) 36.0 (31.338.0,
2640)
32.0 (29.033.5,
2436)
0.02
BMI
Median (IQR, Range) 27.3 (22.430.3,
19.535.7)
25.6 (22.827.8,
21.138.4)
0.53
Number of
miscarriages
Median (IQR, Range) 5.5 (5.07.0, 314) 8.0 (5.09.5, 314) 0.36
Baseline CFU count
Median (IQR, Range) 8.5 (4.517.8, 174) 12.0 (6.345.8,
278)z
0.49
Mean (SD) 16.1 (19.6) 24.2 (25.6)
Second biopsy CFU
count
Median (IQR, Range) 14.0 (8.029.0,
3145)z
11.0 (5.537.5,
398)
0.65
Mean (SD) 27.7 (35.8) 25.1 (27.3)
Timing of baseline
biopsy
Median (IQR, Range) 7.0 (7.08.0)* 7.5 (7.08.0) 0.99
Timing of second
biopsy
Median (IQR, Range) 8.0 (7.09.0)* 7.5 (7.08.8) 0.78
y Mann-Whitney U test.
z data missing for one participant.
* timing of biopsy denotes days following the pre-ovulatory LH surge. Note
that CFU counts are per 1500 EnSC.
Fig. 2. Change in CFU count after 3 cycles of sitagliptin or placebo. The median increase
in CFU count in the second compared to the baseline biopsy was +7 per 1500 EnSC and
0.5 per 1500 EnSC in the sitagliptin and placebo group, respectively (P<0.01). Box-
plots present the median, upper and lower quartiles with whiskers calculated using
Tukey’s method.
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pregnancy outcome
The median endometrial thickness at baseline was 9¢0 mm [inter-
quartile range (IQR): 8.510.0 mm] and 8.9 mm (IQR: 7.29.7 mm)
in the placebo and sitagliptin groups, respectively. Median endome-
trial thickness at the time of the second biopsy was 9.6 mm (IQR:
7.710.3 mm) and 8.0 mm (IQR: 7.210.6 mm) in the placebo and
sitagliptin groups, respectively. Hence, endometrial thickness was
within the expected midluteal range for all participants and not sig-
niﬁcantly different between the placebo and sitagliptin groups, either
at baseline or at the time of the second biopsy (P>0.05, Kruskal-
Wallis test).
Compliance to study medication was high. Out of 33 participants
who completed the study, 32 demonstrated near full compliance
(>98%). Study medication compliance was 50% for one participant
randomised to placebo. A questionnaire with Likert scale responses
and space for free text comments showed that all participants agreed
or agreed strongly that taking part in the study was worthwhile,
would recommend the study to others, and found that taking the
medication was easy. The only adverse event reported by more than
one participant was headache, which occurred in 7 and 4 participants
in the placebo and sitagliptin group, respectively; and therefore not
attributable to study medication. Supplementary Table S1 lists all
reported side-effects.Table 2
CFU count after 3 cycles of sitagliptin or placebo (second biopsy).
Mean CFU county R
Sitagliptin Placebo Unadjusted analysis
All data 27.7 25.1 1.10 (0.96, 1.26), P = 0.15z
Subgroup datay 14.4 11.0 1.31 (1.04, 1.67), P = 0.02
y Excludes data for participants with outlying CFU counts.
z Pre-speciﬁed primary outcome measure.
* Pre-speciﬁed secondary analysis. Note CFU counts are per 1500 EnSC.
Please cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://doWe recorded the outcome of the ﬁrst pregnancy within 12
months following completion of the study. Out of 33 participants
who completed the study, 25 reported a pregnancy outcome within
this timeframe. In the sitagliptin group, there were 8 live births, one
termination of pregnancy at 16 weeks for a foetal abnormality (cere-
bellar agenesis), and 3 spontaneous pregnancy losses before 12
weeks of gestation. Cytogenetic analysis was performed in 2 of 3 mis-
carriage cases and both showed foetal aneuploidy (trisomy 22 and
triploidy). In the placebo group, there were 7 live births and 6 sponta-
neous pregnancy losses before 12 weeks. Cytogenetic analysis was
performed in one case and showed normal foetal karyotype. It is
important to note that this study was not powered to assess the effect
of pre-pregnancy sitagliptin treatment on pregnancy outcomes.3.4. Explorative investigations: oral sitagliptin inhibits decidual
senescence but not endometrial DPP4 activity
DPP4 is a known marker of glandular differentiation during the
midluteal phase of the cycle [50]. DPP4 is also a widely used endome-
trial receptivity marker gene [51]. To explore the mechanisms of sita-
gliptin actions in the endometrium, we ﬁrst measured DPP4 activity
in paired snap-frozen baseline and second biopsies from individual
participants in the placebo group (n = 15) and sitagliptin group
(n = 15). In addition, paired placebo (n = 16) and sitagliptin (n = 16)ate ratio (95% Conﬁdence interval), P value
Adjusted for baseline count Adjusted for baseline count and age*
1.51 (1.31, 1.73), P<0¢01 1.52 (1.32, 1.75), P<0.01
1.43 (1.13, 1.80), P<0.01 1.67 (1.29, 2.17), P<0.01
trial mesenchymal stem-like progenitor cells: A randomised, double-
i.org/10.1016/j.ebiom.2019.102597
Table 3
Results of the random effects adjusted Poisson regression model.
Rate ratio: second to baseline biopsy
(95% conﬁdence interval), P value
Rate ratio: sitagliptin to placebo
(95% conﬁdence interval), P value
Sitagliptin Placebo Baseline Second biopsy
All data 1.68 (1.44, 1.97), P<0.01 1.08 (0.94, 1.24), P = 0.26 0.97 (0.71, 1.31), P = 0.82 1.49 (1.12, 2.00), P<0.01
Subgroupy 1.88 (1.47, 2.41), P<0.01 1.27 (0.97, 1.66), P = 0.08 1.01 (0.71, 1.43), P = 0.95 1.49 (1.09, 2.04), P<0.01
y Excludes data from participants with high baseline CFU (>20 colonies per 1500 EnSC).
a
0.001
0.01
0.1
1
10
Placebo Sitagliptin
1
10
100
1000
Placebo Sitagliptin
BB SB BB SB BB SB BB SB
b
Fig. 3. Oral sitagliptin does not inhibit endometrial DPP4. a) DPP4 activity (left panel) was measured in tissue lysates from paired baseline and second biopsies (BB and SB, respec-
tively) obtained from participants in the placebo (n = 15) and sitagliptin (n = 15) groups. DPP4 activity was normalized to total protein content. b) DPP4 mRNA level, normalized to
L19 and expressed as arbitrary units, was measured by RT-qPCR in paired baseline and second biopsies obtained from participants randomised to placebo (n = 16) or sitagliptin
(n = 16). DPP4 expression and activity were not signiﬁcantly different between the groups (P>0.025, Wilcoxon Matched Pairs Signed Ranks test with Sidak correction).
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levels by RT-qPCR. As shown in Fig. 3 and Supplementary Table S3,
endometrial DPP4 activity and expression were not different
between the baseline and second biopsies in the placebo or sitaglip-
tin group (P>0.025, Wilcoxon test), indicating that the dose of sita-
gliptin (100 mg daily) was insufﬁcient to inhibit DPP4 activity at
tissue level.
We also explored if sitagliptin impacts on the clonogenicity of pri-
mary EnSC or EnEC isolated from independent midluteal biopsies. As
shown in Supplementary Figure S1A, DPP4 activity was 3-fold higher in
primary EnEC when compared to EnSC (P = 0.003, Mann-Whitney U
test). Exposure of primary EnEC or EnSC to pharmacological concentra-
tions of sitagliptin inhibited DPP4 activity by ~90% (Suppl. Fig S1B).
Next, we performed CFU assays on cultured EnSC seeded at very low
cell density in the presence or absence of 100 mM sitagliptin for
10 days. No difference in colony-forming efﬁciency of EnSC was
observed between cultures treated with or without sitagliptin (Suppl.
Fig S1C; P>0.05, Wilcoxon test). To test the impact on epithelial progen-
itor cells, we made use of a recently published protocol that enables for-
mation of gland organoids from single endometrial epithelial progenitor
cells [48]. Again, addition of sitagliptin to the expansion medium had no
impact on endometrial gland organoid forming efﬁciency compared to
control cultures (Suppl. Fig S1D; P>0.05, Wilcoxon test).
Next, we examined the expression of decidual marker genes in
paired baseline and second biopsies from the placebo (n = 16) and
sitagliptin (n = 16) groups. Induction of PRL and IGFBP1 expression is
widely used to monitor the decidual response in cultured EnSC [12].
However, these marker genes do not discriminate between decidual
cells and senescent decidual cells [26]. By contrast, SCARA5 and DIO2
are marker genes of decidual cells and senescent decidual cells,
respectively, both in vitro and in vivo [26]. PRL and IGFBP1 transcript
levels were not signiﬁcantly different in the second biopsy compared
to the baseline biopsy in either the placebo or treatment group
(Suppl. Fig. S2 and Table S3, P>0.025, Wilcoxon test). By contrast,
sitagliptin treatment but not placebo resulted in a signiﬁcantPlease cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://doreduction in mean DIO2 mRNA levels in the second biopsy compared
to the baseline biopsy (Suppl. Table S3 and Fig. 4A, left panel [median:
0.96 arbitrary units (a.u.) vs. 3.26 a.u., respectively, P = 0.0182, Wil-
coxon test], whereas SCARA5 mRNA levels were not altered signiﬁ-
cantly (Suppl. Table S3 and Fig. 4A, right panel; P>0.025). The
average reduction in DIO2 expression in paired biopsies was 44.4%
(range: 91.5% to +26%). Thus, sitagliptin treatment not only
increases the abundance of eMSCs in the endometrium but also reba-
lances the relative abundance of decidual cell subpopulations, as
measured by the fold-change in SCARA5/DIO2 ratio (Fig. 4B), by atten-
uating decidual senescence.
Discussion
This study reports on the feasibility of using oral sitagliptin
(100 mg daily) to increase the abundance of eMSC in RPL patients.
The primary outcome of this randomised, double-blind, placebo-con-
trolled trial was CFU counts after 3 cycles of sitagliptin or placebo.
Unadjusted analysis showed no statistically signiﬁcant difference in
CFU counts between the groups but this was accounted for by the
unanticipated magnitude of interpatient variation in CFU counts. This
variability in CFU counts also suggests that the severity of the RM
phenotype is not solely attributable to loss of eMSC. Baseline CFU
counts ranged from 1 to 78 colonies per 1500 cells seeded (0.07% to
5.2%, respectively), although only 8 subjects had CFU counts of more
than 20 colonies per 1500 cells (>1.3%). When adjusted for baseline
CFU count, the mean CFU count in the second biopsy was 51% higher
in the sitagliptin group compared to the placebo group. Compared to
the baseline biopsy, sitagliptin given for 3 menstrual cycles increased
CFU counts on average by 68%. By contrast, there was no signiﬁcant
change in CFU counts in the placebo group, attesting to the robust-
ness of the endometrial response to oral sitagliptin. The lack of a dis-
cernible effect in the placebo group demonstrated that the biopsy
procedure per se had no sustained impact on the abundance of eMSC.
Notably, participants randomised to the sitagliptin treatment weretrial mesenchymal stem-like progenitor cells: A randomised, double-
i.org/10.1016/j.ebiom.2019.102597
a-1 1 2 3
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Fig. 4. Oral sitagliptin inhibits decidual senescence. a) DIO2 and SCARA5mRNA levels, normalized to L19 and expressed as arbitrary units, were measured by RT-qPCR in paired base-
line and second biopsies (BB and SB, respectively) obtained from participants in the placebo (n = 16) and sitagliptin (n = 16) groups.* indicates P = 0.0182 (Wilcoxon Matched Pairs
Signed Ranks test with Sidak correction). Note logarithmic scale. b) The relative change in the ratio of SCARA5 and DIO2 transcripts is shown in relation to the change in CFU counts
in paired endometrial biopsies from the placebo (red dots) and sitagliptin (green dots) groups.
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previous study [52], we found no evidence of a signiﬁcant impact of
age on either baseline CFU counts or on the response to sitagliptin.
Explorative investigations indicated that the increase in eMSC in
response to sitagliptin is biologically meaningful and associated with a
signiﬁcant reduction in senescent decidual cells. This conclusion is
based on expression analysis of DIO2 and SCARA5, which are marker
genes of decidual cells and senescent decidual cells, respectively [26].
DIO2 encodes iodothyronine deiodinase 2, which catalyses the conver-
sion of prohormone thyroxine (T4) into bioactive triiodothyronine
(T3). This gene is repressed by progesterone in decidual cells but not in
progesterone-resistant senescent decidual cells [26,53]. By contrast,
SCARA5, coding the L-ferritin receptor (scavenger receptor class A
member 5), is a progesterone-dependant marker gene of decidual cells
[26,54]. Sitagliptin given over 3 cycles selectively reduced endometrial
DIO2 mRNA expression by an average of 44¢4%, signifying a reduction
in senescent decidual cells during the implantation window. Taken
together, these observations indicate that pre-pregnancy sitagliptin
improves the peri‑implantation endometrium by simultaneously
increasing tissue plasticity and decreasing decidual senescence.
Oral sitagliptin (100 mg daily) did not inhibit uterine DPP4
expression or activity. We also found no evidence that sitagliptin
impacts directly on the clonal capacity of eMSCs or organoid forma-
tion efﬁcacy of epithelial progenitor cells. Taken together, our explor-
atory observations are compatible with the hypothesis that oralPlease cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://dositagliptin inhibits DPP4-dependant inactivation of SDF-1 in the cir-
culation [55,56]; and that homing and engraftment of BMDC in
cycling endometrium is dependant on the level of circulating bioac-
tive SDF-1 [32,34,36].
The ability of gliptins to enhance regeneration of damaged tissues
has been explored in other organs but by and large the clinical results
have been disappointing. For example, intracoronary administration
of BMDC has been shown to improve recovery of left ventricular con-
tractile function in patients with acute myocardial infarction [57],
whereas a combination of granulocyte-colony stimulating factor (G-
CSF)-dependant mobilisation of BMDC followed by sitagliptin treat-
ment (100 mg for 28 days) failed to improve cardiac function [58].
However, a particular advantage of the endometrium over other tis-
sues, such as heart or kidney, is that DPP4 inhibitors can be initiated
prior or during (menstrual) tissue injury and sustained over multiple
cycles. Our feasibility trial also demonstrated the acceptability of pre-
pregnancy sitagliptin treatment in RPL patients. Drug compliance
was high and no adverse events were reported. Although the trial
was not designed or powered to assess to assess pregnancy outcome,
only 3 spontaneous miscarriages were reported out of 12 pregnancies
in the sitagliptin group, two of which were found to be caused by foe-
tal aneuploidies.
A pharmacological approach to increase endometrial progenitor
populations could be useful in the management of other intractable
reproductive disorders. For example, in a murine model of thintrial mesenchymal stem-like progenitor cells: A randomised, double-
i.org/10.1016/j.ebiom.2019.102597
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increased following treatment with either BMDC or SDF-1 [38]. A
recent non-controlled study reported that autologous cell therapy in
conjunction with hormonal replacement therapy temporarily
improves endometrium thickness, as well as the volume and duration
of menses, in patients with refractory Asherman's syndrome or endo-
metrial atrophy [59]. This approach requires mobilization of BMDC
using G-CSF, isolation of CD133+ endothelial progenitors through
peripheral blood aphaeresis, and ﬁnally delivery of cells into the spiral
arterioles by catheterization under angiography. Although we found
no evidence that sitagliptin increases endometrial thickness during
the luteal phase in this study, it should be noted that none of the par-
ticipants had an abnormally thin midluteal endometrium.
4.1. Limitations of the study
A drawback of the study was the reliance on an indirect measure
of eMSC, i.e. CFU assays that take 10 days to complete. As aforemen-
tioned, the interpatient variation in this assay was greater than antic-
ipated. Also, the analysis of decidual subpopulations was based on
RT-qPCR measurements of marker genes. While a recent study dem-
onstrated that endometrial SCARA5 and DIO2 expression differs
between control subjects and RPL patients [26], their value in pre-
dicting pregnancy outcome has not yet been tested. The scope of our
explorative investigations was limited and the impact of oral sitaglip-
tin on other constituents of the endometrium, such as endothelial
cells and EnEC, warrants further investigation. Another limitation of
the study is that it did not examine if the endometrial response was
transient or sustained following cessation of treatment. Further, at
least 11 different DPP4 inhibitors have now been approved for the
management of type-2 diabetes worldwide [60]. Whether or not all
these preparations are equivalent in terms of the endometrial
response requires further investigation. As articulated before, this
feasibility trial was not powered to assess the effect of pre-pregnancy
sitagliptin treatment on live birth rates in RPL patients.4.2. Patient selection and drug dosing and timing considerations
Our study raises a number of issues that should be considered in
future studies. The ﬁrst issue relates to selection of RPL patients most
likely to beneﬁt from treatment with sitagliptin. Ideally, recruitment in
future studies should be based on pre-pregnancy screening for eMSC
deﬁciency and/or excessive decidual senescence. However, it is
impractical to use CFU assays in large-scale clinical studies and the use
of decidual marker genes for screening purposes requires further vali-
dation. Alternatively, patients could be selected on basis of risk factors
associated with euploid pregnancy loss, including the number of previ-
ous miscarriages [8,9], a prior history of euploid pregnancy loss [6],
and obesity [61]. Second, in this study we opted for continuous sita-
gliptin treatment over 3 cycles based on the assumption that the effect
on eMSC may be cumulative over multiple menstrual ‘injuries’. It is
possible that homing and engraftment of BMDC in the endometrium is
physiologically restricted to the proliferative phase of the cycle. This
conjecture is supported by murine studies demonstrating that oestra-
diol coordinates the induction of SDF-1 expression in EnSC with the
expression of the SDF-1 receptor, C-X-C motif chemokine receptor 4
(CXCR4), in BMDC [37]. The National Institute for Health and Care
Excellence (NICE) in the UK advises against the use of sitagliptin in
pregnancy, a risk that could be avoided by restricting sitagliptin treat-
ment to the proliferative phase, although the efﬁcacy of this approach
requires further evaluation. Another consideration relates to the opti-
mal dose of sitagliptin for the purpose of miscarriage prevention in
RPL. In this study, we used 100 mg of sitagliptin daily, which is the rec-
ommended dose for glycaemic control in type 2 diabetes [62]. Higher
doses of sitagliptin purportedly result in more sustained plasma DPP4Please cite this article as: S. Tewary et al., Impact of sitagliptin on endome
blind placebo-controlled feasibility trial, EBioMedicine (2019), https://doinhibition [63], which conceivably could further enhance or accelerate
the engraftment of BMDC in the endometrium.
4.3. Conclusions
Sitagliptin increases the abundance of eMSC in midluteal endome-
trium and reduces decidual senescence. A large-scale clinical trial
evaluating the impact of preconception sitagliptin treatment on preg-
nancy outcome in RPL patients is feasible and warranted.
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